Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden

Conclusion Dabigatran is a cost-effective treatment in Sweden, as its incremental cost-effectiveness ratio is below the normally accepted willingness to pay limit.
Source: European Heart Journal - Category: Cardiology Authors: Tags: Arrhythmia/electrophysiology Source Type: research